Third degree AV block primary prevention

Jump to navigation Jump to search

Third degree AV block Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Third degree AV block from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Third degree AV block primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

slides

Images

American Roentgen Ray Society Images of Third degree AV block primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Third degree AV block primary prevention

CDC on Third degree AV block primary prevention

Third degree AV block primary prevention in the news

Blogs on Third degree AV block primary prevention

Directions to Hospitals Treating Third degree AV block

Risk calculators and risk factors for Third degree AV block primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Zand, M.D.[2]

Overview

Effective measurement for primary prevention of atrioventricular block due to dogoxin toxicity in patients with renal insufficiency is avoidance of dehydration, electrolytes imbalance and careful monitoring about heart block.

Primary prevention


References

  1. Adamantidis MM, Duriez PR, Vincent AC, Dupuis BA (1983). "Digoxin-induced toxicity and experimental atrioventricular block in dogs. Relation between ventricular arrhythmias and oscillatory afterpotentials". J Pharmacol. 14 (3): 333–49. PMID 6632915.


Template:WikiDoc Sources